Today, psychedelic drug developer Cybin announced that it has received breakthrough therapy designation for CYB003, its deuterated psilocybin analog candidate under development for major depressive disorder (MDD). As such, the company has become the fifth organisation to achieve FDA breakthrough therapy designation status for a psychedelic drug candidate. The announcement comes less than a week…
